Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Payables (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Payables data on record, last reported at $2.5 million in Q3 2025.

  • For Q3 2025, Payables rose 57.54% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $2.5 million, up 57.54%, while the annual FY2024 figure was $1.4 million, 109.72% up from the prior year.
  • Payables reached $2.5 million in Q3 2025 per RANI's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Payables topped out at $2.5 million in Q3 2025 and bottomed at $506000.0 in Q2 2024.
  • Average Payables over 5 years is $1.4 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Payables: plummeted 55.62% in 2023, then soared 255.34% in 2025.
  • A 5-year view of Payables shows it stood at $1.1 million in 2021, then skyrocketed by 35.19% to $1.5 million in 2022, then tumbled by 55.62% to $648000.0 in 2023, then soared by 109.72% to $1.4 million in 2024, then skyrocketed by 81.53% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $2.5 million in Q3 2025, $1.8 million in Q2 2025, and $1.5 million in Q1 2025.